Want to see HK:3390 full AI Analyst Report?
Tycoon Group Holdings Limited (3390) AI Stock Analysis
Tycoon Group Holdings Limited
(HKEX:3390)
The overall score reflects a stock with recovering fundamentals but notable execution and cash-flow risks, supported by only mildly constructive technicals and fair valuation. The most important driver is financial performance: revenue and cash-flow recovery and an improving debt profile are offset by sharply compressed net margins and historically weak cash generation, which constrain upside. Technical indicators suggest short-term support but a still-intact longer-term downtrend, limiting momentum-driven appeal. Valuation at a mid-teens P/E looks acceptable relative to risk, yet the lack of dividends and uncertain earnings trajectory keep the score in the low 60s rather than a higher, more conviction-level rating.
Tycoon Group Holdings Limited (3390) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 219.03M
- Dividend Yield
- ―
- Average Volume (3M)
- 92.16K
- Price to Earnings (P/E)
- 6.9
- Beta (1Y)
- 0.06
- Revenue Growth
- 13.83%
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 199
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
Tycoon Group Holdings Limited Business Overview & Revenue Model
Company Description
Tycoon Group Holdings Limited functions as an investment holding enterprise, specializing in the worldwide distribution and retail of an extensive portfolio of health and wellness products. Its market presence extends across Hong Kong, Mainland China...
How the Company Makes Money
Tycoon Group Holdings Limited makes money primarily by distributing and trading pharmaceutical and healthcare products. Its core revenue model is product sales: the company sources branded and/or generic pharmaceutical products (and potentially other...
Tycoon Group Holdings Limited Financial Statement Overview
Summary
Financial performance is moderately strong, reflecting a clear recovery but ongoing profitability and cash-flow risks. Revenue rebounded with 15.3% growth in 2025 and gross margins remained stable around 22–27%, yet net profit margins collapsed to 1.4% from 24.8% in 2023, highlighting significant earnings volatility and pressure in a competitive pharma market. The balance sheet is relatively solid, with an improved debt-to-equity ratio of 0.80, growing assets and a stable equity base, but low return on equity indicates that capital is not generating robust returns. Cash flow is the weakest area: operating cash flow turned positive in 2025 and free cash flow nearly matched it, but this improvement comes after years of cash burn and a sharp plunge in free cash flow growth, keeping overall financial quality in the mid-range.
Income Statement
68PositiveBalance Sheet
72PositiveCash Flow
55Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.08B | 1.10B | 876.04M | 1.20B | 1.19B | 888.87M |
| Gross Profit | 252.27M | 270.04M | 232.66M | 321.10M | 243.53M | 135.01M |
| EBITDA | 75.98M | 66.46M | 43.35M | 356.41M | 82.89M | 8.91M |
| Net Income | 30.79M | 15.67M | 3.24M | 297.32M | 43.75M | -18.82M |
Balance Sheet | ||||||
| Total Assets | 1.14B | 1.17B | 1.01B | 988.95M | 1.01B | 881.46M |
| Cash, Cash Equivalents and Short-Term Investments | 22.28M | 70.34M | 34.02M | 39.10M | 74.60M | 71.63M |
| Total Debt | 410.29M | 428.05M | 330.98M | 206.16M | 341.60M | 239.08M |
| Total Liabilities | 590.19M | 625.03M | 516.61M | 445.40M | 718.96M | 620.20M |
| Stockholders Equity | 542.58M | 537.00M | 478.85M | 536.23M | 293.64M | 257.92M |
Cash Flow | ||||||
| Free Cash Flow | 23.17M | 96.47M | -78.94M | 7.97M | -64.48M | -50.11M |
| Operating Cash Flow | 23.21M | 96.95M | -76.62M | 11.86M | -63.03M | -42.20M |
| Investing Cash Flow | 14.47M | -25.10M | 48.55M | 45.70M | -9.57M | -26.25M |
| Financing Cash Flow | -55.13M | -35.36M | 25.62M | -92.36M | 68.25M | 14.33M |
Tycoon Group Holdings Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3390, the sentiment is Negative. The current price of 0.24 is above the 20-day moving average (MA) of 0.24, below the 50-day MA of 0.25, and below the 200-day MA of 0.27, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 41.06 is Neutral, neither overbought nor oversold. The STOCH value of 68.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3390.
Tycoon Group Holdings Limited Peers Comparison
Overall Rating
- HK:339063.3Neutral
HK:085854Neutral
HK:239352Neutral
HK:111051Neutral
HK:151846Neutral
HK:149842Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:3390 | 63Neutral | HKD 219.03M | 6.88 | 5.70% | ― | 13.83% | ― |
| HK:0858 | 54Neutral | HKD 147.90M | -0.13 | -154.56% | ― | -7.12% | -523.61% |
| HK:2393 | 52Neutral | HKD 146.77M | -1.48 | -22.16% | ― | -28.07% | 47.54% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:1110 | 51Neutral | HKD 227.44M | 16.80 | 1.89% | 8.45% | -13.82% | 112.24% |
| HK:1518 | 46Neutral | HKD 96.64M | -0.60 | -34.98% | 11.16% | -23.52% | -226.85% |
| HK:1498 | 42Neutral | HKD 123.04M | -4.04 | -21.66% | ― | -6.71% | 43.14% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:3390 | Tycoon Group Holdings Limited | 0.24 | -0.04 | -15.52% | |
| HK:0858 | Extrawell Pharmaceutical Holdings Limited | 0.05 | -0.04 | -44.57% | |
| HK:1110 | Kingworld Medicines Group Ltd. | 0.38 | -0.16 | -29.25% | |
| HK:1498 | PuraPharm Corp. Ltd. | 0.23 | -0.19 | -45.24% | |
| HK:1518 | New Century Healthcare Holding Co. Ltd. | 0.20 | -0.62 | -75.85% | |
| HK:2393 | Yestar Healthcare Holdings Co Ltd | 0.06 | -0.07 | -51.54% |
Tycoon Group Holdings Limited Corporate Events
Tycoon Group Further Delays Circulars on Key Connected Transactions
Tycoon Group Holdings Limited has announced a further delay in sending circulars to shareholders regarding proposed revisions of annual caps for continuing connected transactions with JBM Group and Talent Smart Group, as well as the Foci Distribution...
Tycoon Group Delays Key Circulars on Connected Transactions
Tycoon Group Holdings Limited has announced a delay in sending out two shareholder circulars regarding proposed revisions of annual caps for continuing connected transactions with JBM Group and Talent Smart Group, as well as the Foci Distribution Agr...
Tycoon Group Raises Connected Transaction Caps and Expands JBM Ties
Tycoon Group Holdings is revising the annual caps for certain continuing connected transactions with JBM Group after reviewing distribution agreements and concluding that transaction volumes are likely to exceed previous projections. The terms of the...
Tycoon Group Raises Caps on Connected Transactions With Talent Smart
Tycoon Group Holdings Limited plans to raise the annual caps on continuing connected transactions under its 2025 Master Sale and Purchase Agreement with Talent Smart Group after updated procurement plans showed actual transaction values are likely to...
Tycoon Group Wins Strong Shareholder Backing for Capital Mandates at AGM
Tycoon Group Holdings Limited reported that all resolutions at its annual general meeting on 29 May 2026 were approved by shareholders via poll, with voting rights attached to the company’s entire issued share capital of 894 million shares and...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 06, 2026